Background: Jobelyn® (JB) is a polyherbal formulation with proven benefits on psychosis, a psychiatric disorder, validated in dopamine-agonist models. However, its effect in ketamine, a glutamate antagonist, is linked to schizophrenia's pathology due to N-methyl-D-aspartate (NMDA) receptor hypofunction, which remains largely unknown. Hence, this study investigates the antipsychotic effectsof JB...